Product Theaters & Non-CME Sessions

PDA is happy to announce the Product Theaters/Non-CME educational sessions that will take place at The Hilton Portland during our 74th Annual Meeting. Food and beverage will be provided for attendees at all Product Theaters/Non-CME educational sessions.

*Please note that these are non-CME accredited sessions.

THURSDAY | July 28, 2022
11:45 am - 12:45 pm
Lunch & Product Theater*
Step into Possibility- Discover Olumiant- the first and only FDA approved treatment for adults with Severe Alopecia Areata (AA)
Andrew Blauvelt, MD, Oregon Medical Research Center
Presented by Lilly

THURSDAY | July 28, 2022
4:15 pm - 5:00 pm
Reception & Product Theater*
Join Pfizer | Learn About A Now Approved Oral Rx Treatment for Moderate-to-Severe Atopic Dermatitis
E. James Song, MD, FAAD, University of Washington

Now introducing CIBINQO™ (abrocitinib) for adults with refractory, moderate-to-severe atopic dermatitis. Pfizer Inc., invites you to an engaging, non-CME, educational program during which an atopic dermatitis expert will discuss the efficacy and safety profile of this new treatment option, helping you determine its appropriateness for your patients. Full PI available at 

Presented by Pfizer

FRIDAY | July 29, 2022
12:15 pm - 1:15 pm
Lunch & Product Theater*
A Treatment Option for Patients with Uncontrolled Moderate-to-Severe Atopic Dermatitis
Clive Liu, MD, Bellevue Dermatology Clinic

Learn more about a treatment that may help appropriate patients with uncontrolled moderate-to-severe atopic dermatitis.

Presented by Sanofi and Regeneron Pharmaceuticals, Inc.

SATURDAY | July 30, 2022
12:15 pm - 1:15 pm
Lunch & Product Theater*
Challenging AD Expectations: A Therapy Option That Challenges Treatment Goals for Patients With Refractory, Moderate to Severe Atopic Dermatitis (AD) Who Are Not Adequately Controlled With Other Systemic Drug Products
Andrew Blauvelt, MD, Oregon Medical Research Center

The Objectives of this lecture are to understand the burden of AD, to examine the efficacy and safety of RINVOQ in patients with moderate to severe AD and, finally, to review resources available through RINVOQ Complete

Presented by AbbVie

SUNDAY | July 31, 2022
8:00 am - 8:45 am
Breakfast & Product Theater*
Libtayo: Harnessing the Power of Human Immunity
Dr. Dan Zelac, Scripps Medical Clinic in La Jolla, CA, Cutaneous Tumor Board of Scripps Clinic/Green Hospital, Scripps MD Anderson Partnership

The presentation focuses on NMSC disease awareness, multidisciplinary care as well as the evolving treatment landscape in both BCC/CSCC.

Presented by Regeneron